AKG-Enzyme Composition for Neurogenesis and Brain Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet medical need for alternative and/or improved treatments of disorders involving eosinophilia, neurological and/or neurodegenerative disorders, and for improving brain function, as existing treatments like corticosteroids and imatinib have drawbacks.
Innovation Solution
A composition comprising alpha-ketoglutaric acid (AKG) and enzymes such as lipases, proteases, and amylases, specifically in synergistic amounts, to promote neurogenesis, improve synaptic morphology, and reduce eosinophil counts, addressing conditions like Alzheimer's, Parkinson's, depression, and cognitive disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If corticosteroids or imatinib are used to treat eosinophilia, then eosinophil counts are reduced, but significant side effects and treatment limitations occur
Solution Approach 1:
The patent uses AKG as an intermediary substance that indirectly reduces eosinophil counts through metabolic modulation rather than direct suppression. AKG enters the Krebs cycle and influences cellular metabolism, particularly in eosinophils, leading to reduced survival and decreased counts without the harsh side effects of corticosteroids or imatinib.
Solution Approach 2:
The invention changes the metabolic parameters of eosinophils by introducing AKG, which alters the Krebs cycle activity and cellular energy metabolism. This parameter change in metabolic pathways leads to reduced eosinophil survival and decreased counts without requiring direct cytotoxic or immunosuppressive mechanisms.
2Reliability
If adult neurogenesis is stimulated to treat neurological disorders, then potential treatment benefits for Alzheimer's, Parkinson's, and depression are achieved, but effective and safe treatment methods are lacking
Solution Approach 1:
The patent employs AKG as a multi-functional compound that simultaneously supports neurogenesis, improves synaptic function, and reduces eosinophil counts. This single substance addresses multiple neurological conditions (Alzheimer's, Parkinson's, depression) and inflammatory states, providing versatile treatment coverage without requiring multiple different medications.
Solution Approach 2:
The invention converts the metabolic dysregulation associated with neurological disorders into a therapeutic opportunity by using AKG to restore normal Krebs cycle function. The metabolic abnormalities that contribute to neurodegeneration are reversed through AKG supplementation, turning a harmful metabolic state into a beneficial therapeutic effect.
3Ease of operation
If existing treatments for neurological disorders are used, then some symptom management is achieved, but brain function improvement and neurogenesis promotion are insufficient
Solution Approach 1:
The patent takes preliminary action by promoting neurogenesis and improving synaptic morphology before neurological damage becomes irreversible. AKG supplementation early in the disease process or in preventive settings enhances brain function and creates neural reserve, providing a foundation that protects against future deterioration and improves overall neurological outcomes.
Data Source
AI summary
A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.